AN ACT TO PROHIBIT HEALTH BENEFIT PLANS, PHARMACY BENEFIT MANAGERS AND PRIVATE REVIEW AGENTS FROM SUBJECTING DRUGS PRESCRIBED FOR THE TREATMENT OR PREVENTION OF HIV OR AIDS TO A PRIOR AUTHORIZATION REQUIREMENT, STEP THERAPY, OR ANY OTHER PROTOCOL THAT COULD RESTRICT OR DELAY THE DISPENSING OF THE DRUG; TO AMEND SECTIONS 83-9-36 AND 83-5-909, MISSISSIPPI CODE OF 1972, TO CONFORM; TO BRING FORWARD SECTIONS 83-5-905 AND 43-13-117, MISSISSIPPI CODE OF 1972, FOR THE PURPOSE OF POSSIBLE AMENDMENT; AND FOR RELATED PURPOSES.
Impact
The passage of HB144 represents a significant shift in state health policy regarding the treatment of HIV and AIDS. By removing administrative barriers to accessing necessary medications, the bill is expected to improve health outcomes for individuals living with HIV. Furthermore, it modifies existing definitions and regulations within the Mississippi Code, particularly regarding health benefit plans, thereby aligning them with the bill's objectives to streamline access to critical health care services.
Summary
House Bill 144 aims to enhance access to antiretroviral (ARV) drugs prescribed for the treatment or prevention of HIV and AIDS by prohibiting certain restrictions imposed by health benefit plans, pharmacy benefit managers, and private review agents. Specifically, the bill disallows these entities from requiring prior authorization or implementing step therapy protocols that may delay or restrict the dispensing of these vital medications. This legislative effort is founded on the intention to ensure patients can receive the appropriate treatments without unnecessary administrative hurdles.
Contention
There are potential points of contention surrounding HB144, particularly regarding the implications for cost management and regulatory oversight. Critics may raise concerns on how this legislation could affect insurance premiums or lead to increased expenditures on medication without the usual checks such as prior authorizations. Moreover, there may be discussions on how this change reconciles with the need for managed care frameworks that aim to control costs while ensuring patient access.